Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. COCP
COCP logo

COCP Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cocrystal Pharma Inc (COCP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
1.310
1 Day change
-9.03%
52 Week Range
2.670
Analysis Updated At
2026/05/08
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

COCP is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock shows no strong proprietary buy signal, no recent news catalyst, weak operating results, and a neutral-to-soft technical setup. With no clear trend advantage and no positive event-driven momentum, the better call is to avoid buying now and wait for a stronger setup.

Technical Analysis

COCP is trading at 1.40, very close to its pivot level of 1.384, which suggests the stock is sitting in a short-term equilibrium zone rather than a clear breakout area. RSI_6 at 48.82 is neutral and does not indicate oversold strength. MACD histogram is -0.0201, below zero, though negatively contracting, which means bearish momentum is present but not strongly accelerating. Moving averages are converging, pointing to a range-bound or indecisive trend. Key levels to watch are resistance at 1.46 and support at 1.307. Overall, the current price trend is weakly neutral to slightly bearish, not an attractive long-term entry.

Positive Catalysts

  • No news in the recent week means there are no fresh event-driven catalysts. The stock is close to pivot support, which can sometimes provide a short-term stabilization point. Consensus-style pattern analysis suggests only modest near-term movement potential, but not a strong upside setup.

Neutral/Negative Catalysts

  • No news flow in the last week removes any obvious momentum catalyst. Hedge funds are neutral and insiders are neutral, so there is no sign of accumulation from informed buyers. AI Stock Picker shows no signal today, and SwingMax also shows no recent signal, removing two proprietary bullish triggers. The stock trend model points to only 0.07% next-week expected change and -2.66% next-month change, which is weak for a long-term buy.

Financial Performance

In 2025/Q4, COCP reported revenue of 0, with no year-over-year growth. Net income fell to -2,426,000, down 25.72% YoY, and EPS dropped to -0.18, down 43.75% YoY. Gross margin was 0. This indicates the latest quarter remained loss-making with deteriorating earnings performance and no meaningful revenue growth, which is unfavorable for a beginner seeking a long-term investment.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no evidence of a favorable recent Wall Street revision. Based on the available data, Wall Street pros would likely lean cautious: the upside case is weak because of missing growth, no news catalyst, neutral insider/hedge fund activity, and no valuation support. The downside case is stronger because earnings remain negative and the technical picture lacks momentum.

Wall Street analysts forecast COCP stock price to rise
1 Analyst Rating
Wall Street analysts forecast COCP stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.440
sliders
Low
10
Averages
10
High
10
Current: 1.440
sliders
Low
10
Averages
10
High
10
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$7 -> $6
AI Analysis
2025-06-21
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$7 -> $6
AI Analysis
2025-06-21
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Cocrystal Pharma to $6 from $7 and keeps a Buy rating on the shares. The firm says CDI-988 demonstrated "further promise" via activity against emergent norovirus variants. It cites anticipated equity dilution for the target cut.

People Also Watch